Immunoassay Market Size & Growth Forecast 2027–2036, By Segments (Product, Specimen, End-use, Technology, Application), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Immunoassay Market size was around USD 29.32 billion in 2026 and is slated to grow at a 4.4% CAGR from 2027 to 2036, surpassing USD 45.1 billion by 2036. The industry revenue for 2027 is calculated at USD 30.41 billion.
Get more details on this report
Request Free Sample ReportImmunoassay Market Intelligence Snapshot
Regional Market Dynamics
- North America held a 50.24% market share in 2026, supported by advanced diagnostic infrastructure, automated laboratory workflows, established reimbursement systems, and consistently high testing volumes.
- Asia Pacific is projected to grow at a 4.33% CAGR as laboratory capacity expands, diagnostic access improves, and healthcare providers increase adoption of immunoassay testing for disease detection and monitoring.
Segment Momentum
- Reagents & Kits held a 64.12% share in 2026 because every immunoassay test requires consumables, creating recurring procurement demand across laboratories, hospitals, and diagnostic facilities.
- Urine is the fastest-growing specimen segment, driven by its non-invasive collection process, ease of handling, and suitability for screening programs seeking greater convenience and accessibility.
Market Expansion Drivers
- Increasing adoption of precision medicine driving biomarker-based immunoassay testing demand.
- Rising prevalence of cancer and autoimmune disorders accelerating advanced diagnostic assay utilization.
- Expanding point-of-care immunodiagnostics increasing decentralized testing capabilities across healthcare systems.
Leading Market Participants
- Top players in the immunoassay market include Abbott Laboratories (United States), F. Hoffmann-La Roche Ltd. (Switzerland), Siemens Healthineers AG (Germany), Danaher Corporation (United States), Thermo Fisher Scientific Inc. (United States), bioMérieux SA (France), Becton, Dickinson and Company (United States), Sysmex Corporation (Japan), Bio-Rad Laboratories, Inc. (United States), QuidelOrtho Corporation (United States).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 29.32 billion
- 2027 Estimated Market Size: USD 30.41 billion.
- Projected Market Size: USD 45.1 billion by 2036
- Growth Forecast: 4.4% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Reagents & Kits (Product) | Blood (Specimen) | Hospitals (End-use) | Enzyme Immunoassays (EIA) (Technology) | Infectious Disease Testing (Application)
- Emerging Opportunity Segment: Software & Services (Product) | Urine (Specimen) | Clinical Laboratories (End-use) | Rapid Test (Technology) | Oncology (Application)
Market Growth Drivers and Industry Trends
Increasing adoption of precision medicine driving biomarker-based immunoassay testing demand
Increasing use of individualized treatment strategies will drive the immunoassay market growth as healthcare providers require reliable biomarker information to characterize diseases and support treatment decisions. Immunoassays can detect and quantify specific proteins, hormones, antibodies, antigens, and other biological markers, making them valuable for patient stratification and disease monitoring. As precision medicine increasingly emphasizes treatment selection based on individual biological characteristics, demand is expanding for testing platforms that can provide consistent biomarker measurements across clinical and laboratory settings.
Rising prevalence of cancer and autoimmune disorders accelerating advanced diagnostic assay utilization
The immunoassay market is expanding alongside the growing diagnostic burden associated with cancer and autoimmune disorders, where detection and monitoring of relevant biological markers can support clinical decision-making. Immunoassay-based techniques are used to identify disease-associated substances and immune responses, helping healthcare professionals assess disease status and monitor patient conditions over time. Increasing demand for earlier diagnosis, treatment monitoring, and differentiated diagnostic workflows is encouraging laboratories and healthcare facilities to adopt more advanced assay technologies for complex disease management.
Expanding point-of-care immunodiagnostics increasing decentralized testing capabilities across healthcare systems
Expansion of decentralized healthcare delivery is strengthening the immunoassay market as point-of-care platforms allow diagnostic testing to be performed closer to patients rather than relying exclusively on centralized laboratories. Portable and rapid immunodiagnostic systems can support timely clinical decisions in hospitals, outpatient facilities, community settings, and other care environments where rapid results are valuable. Improvements in assay sensitivity, portability, workflow simplicity, and instrument integration are enabling broader deployment of immunoassay-based testing across healthcare settings with varying infrastructure capabilities.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Increasing adoption of precision medicine driving biomarker-based immunoassay testing demand | 2.00% | High | North America, Europe, Asia Pacific | High | Mid Term |
| Rising prevalence of cancer and autoimmune disorders accelerating advanced diagnostic assay utilization | 1.80% | High | North America, Europe | High | Near Term |
| Expanding point-of-care immunodiagnostics increasing decentralized testing capabilities across healthcare systems | 1.40% | Moderate | Asia Pacific, Latin America | Emerging | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
North America held a 50.24% share of the immunoassay market in 2026, underpinned by advanced diagnostic infrastructure, widespread laboratory testing, and strong adoption of immunoassay technologies across clinical diagnostics, pharmaceutical research, and life sciences applications. The region benefits from sophisticated healthcare systems and continued demand for accurate detection of infectious diseases, hormones, biomarkers, and other clinical indicators. Ongoing advances in diagnostic automation and increasing emphasis on early disease detection further support regional demand.
Asia Pacific (Fastest-Growing Region)
Asia Pacific represents the fastest-growing region as healthcare infrastructure expands and diagnostic testing becomes more accessible. Rising prevalence of chronic and infectious diseases is increasing the need for reliable laboratory diagnostics, while investments in hospitals and clinical laboratories are improving testing capacity. Growing adoption of automated diagnostic platforms, greater healthcare awareness, and increasing research activity are also accelerating the use of immunoassay technologies across the region.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Laboratory Quality ExcellenceGermany focuses on highly reliable immunoassay systems that meet demanding laboratory quality and regulatory standards. Diagnostic providers invest in precision testing technologies and workflow optimization to support hospitals, research institutions, and specialized clinical laboratories.
France 🇫🇷
Specialized Clinical TestingFrance emphasizes immunoassay technologies for disease monitoring, preventive healthcare, and specialized diagnostic services. Laboratories continue upgrading testing capabilities with automated platforms that enhance analytical consistency and broaden clinical testing applications.
Italy 🇮🇹
Diagnostic Workflow OptimizationItaly strengthens its immunoassay market by modernizing laboratory operations and expanding access to automated diagnostic systems. Healthcare institutions prioritize dependable testing platforms that improve operational efficiency while supporting diverse clinical and hospital diagnostic requirements.
Japan 🇯🇵
Precision Diagnostic InnovationJapan advances the immunoassay market through sophisticated diagnostic technologies designed for accuracy and operational consistency. Manufacturers prioritize compact, high-performance analyzers that integrate efficiently into healthcare facilities and advanced laboratory environments.
South Korea 🇰🇷
Smart Laboratory AdoptionSouth Korea is expanding immunoassay deployment through digitally connected laboratory infrastructure and advanced diagnostic platforms. Healthcare providers increasingly adopt automated testing solutions that improve workflow efficiency and support timely clinical decision-making.
United States 🇺🇸
High-Throughput DiagnosticsThe U.S. immunoassay market emphasizes automation, laboratory efficiency, and expanding diagnostic applications. Healthcare organizations continue adopting advanced immunoassay platforms that improve testing capacity while supporting personalized medicine and routine clinical diagnostics.
Segment Leadership and Growth Trends
Immunoassay Market Share (%), by Product, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportProduct Segment Analysis: Reagents & Kits (Largest Segment) vs Software & Services (Fastest-Growing Segment)
Reagents and kits dominated the immunoassay market with a 64.12% share in 2026, owing to their essential and recurring role in conducting diagnostic and analytical tests. Immunoassay procedures depend on specialized reagents, antibodies, calibrators, and test components to detect and measure target substances accurately. The high volume of routine diagnostic testing across hospitals, laboratories, and research settings supports sustained demand, while the expanding use of immunoassays for disease detection and health monitoring further reinforces the segment's dominant position in 2026.
The software and services segment is the fastest-growing product segment, driven by increasing laboratory automation, digital integration, and demand for efficient data management. Advanced software supports test result analysis, workflow optimization, instrument connectivity, and quality control, while service offerings help maintain reliable operation of increasingly sophisticated diagnostic systems. The growing focus on laboratory efficiency and connected healthcare infrastructure is accelerating demand for integrated software and service solutions.
Specimen Segment Analysis: Blood (Largest Segment) vs Urine (Fastest-Growing Segment)
The blood specimen segment held the largest share of the immunoassay market at 44.03% in 2026, supported by its extensive use across clinical diagnostics and disease monitoring. Blood samples provide access to a broad range of biomarkers, antibodies, hormones, proteins, and other analytes, making them highly suitable for numerous immunoassay applications. The established role of blood testing in hospitals, diagnostic laboratories, and routine health assessments continues to underpin the segment's leading position.
The urine specimen segment is the fastest-growing segment, benefiting from the convenience and non-invasive nature of urine collection. Urine-based immunoassays are widely applicable in screening and diagnostic settings where rapid, accessible, and patient-friendly testing is important. Increasing demand for simplified testing procedures, broader adoption of point-of-care diagnostics, and the suitability of urine samples for various screening applications are supporting the segment's expansion.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Product | Reagents & Kits, Analyzers/Instruments, Software & Services | Reagents & Kits | Software & Services |
| Specimen | Blood, Saliva, Urine, Others | Blood | Urine |
| End-use | Hospitals, Blood Banks, Clinical Laboratories, Pharmaceutical and Biotech Companies, Academic Research Centers, Others | Hospitals | Clinical Laboratories |
| Technology | Radioimmunoassay (RIA), Enzyme Immunoassays (EIA), Chemiluminescence Immunoassays (CLIA), Fluorescence Immunoassays (FIA), Rapid Test, Others | Enzyme Immunoassays (EIA) | Rapid Test |
| Application | Therapeutic Drug Monitoring, Oncology, Cardiology, Endocrinology, Infectious Disease Testing, Autoimmune Diseases, Others | Infectious Disease Testing | Oncology |
Competitive Landscape and Market Positioning
Major players in the immunoassay market:
1. Abbott Laboratories (United States)
2. F. Hoffmann-La Roche Ltd. (Switzerland)
3. Siemens Healthineers AG (Germany)
4. Danaher Corporation (United States)
5. Thermo Fisher Scientific Inc. (United States)
6. bioMérieux SA (France)
7. Becton Dickinson and Company (United States)
8. Sysmex Corporation (Japan)
9. Bio-Rad Laboratories Inc. (United States)
10. QuidelOrtho Corporation (United States)
The immunoassay market is experiencing rapid innovation driven by demand for highly sensitive and automated diagnostic solutions. Companies are introducing advanced assay platforms that support faster detection, multiplex testing, and improved clinical accuracy across healthcare applications. Increased integration of automation and digital analysis tools is further strengthening efficiency and competitiveness within the immunoassay market.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories (United States) | |||||||
| F. Hoffmann-La Roche Ltd. (Switzerland) | |||||||
| Siemens Healthineers AG (Germany) | |||||||
| Danaher Corporation (United States) | |||||||
| Thermo Fisher Scientific Inc. (United States) | |||||||
| bioMérieux SA (France) | |||||||
| Becton Dickinson and Company (United States) | |||||||
| Sysmex Corporation (Japan) | |||||||
| Bio-Rad Laboratories Inc. (United States) | |||||||
| QuidelOrtho Corporation (United States). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| MeMed | Apr-26 | MeMed received CE Mark approval for its rapid host-response test, which differentiates between bacterial and viral infections in approximately 20 minutes. This regulatory milestone supports the integration of sophisticated immunoassay-based diagnostic solutions into routine clinical workflows. |
| QuidelOrtho Corporation | Feb-26 | QuidelOrtho entered a strategic supply agreement with Lifotronic Technology to expand its global immunoassay portfolio with new analyzer platforms and over 25 assays. The partnership enhances its high-throughput diagnostic offerings and scales commercial reach across Europe, Asia-Pacific, Latin America, and the Middle East & Africa. |
| Fujirebio | Jan-26 | Fujirebio launched the Lumipulse G pTau 217 CSF assay for its automated LUMIPULSE G analyzers. This development expands chemiluminescent enzyme immunoassay-based neurological testing capabilities, addressing the growing demand for automated, high-throughput biomarker measurement in Alzheimer’s disease research and diagnostics. |
| Siemens Healthineers | Dec-25 | Siemens Healthineers partnered with ALZpath to integrate the pTau217 antibody into a new in vitro diagnostic assay for Alzheimer’s disease. This strategic collaboration strengthens the company’s neurodegenerative disease immunoassay portfolio and advances its capability to provide standardized biomarker testing. |
| ARCHIMED Diagnostics | Oct-25 | ARCHIMED Diagnostics acquired ARK Diagnostics in a transaction valued at $428 million. This acquisition expands the firm's specialty immunoassay in vitro diagnostics portfolio and strengthens its underlying diagnostics platform capabilities. |
| Spear Bio | Aug-25 | Spear Bio established a strategic distribution partnership with Bio-Techne to accelerate the commercialization of its next-generation, ultrasensitive immunoassay technology. The collaboration targets both life science research and clinical diagnostics sectors to drive the adoption of its proprietary platform. |
| Quanterix Corporation | Jun-25 | Quanterix secured Class 1 Medical Device registration in South Korea for its HD-X Simoa Immunoassay Analyzer. This regulatory approval facilitates the expansion of its ultra-sensitive immunoassay platform within the Asia-Pacific region, increasing market access for advanced protein analysis. |
| T&D Diagnostics | Apr-25 | T&D Diagnostics commenced domestic manufacturing of its Starkwert FIA product range in India. This investment in local production capabilities enhances the company's ability to supply fluorescence immunoassay diagnostic solutions to the regional market. |
| bioMérieux | Jan-25 | bioMérieux acquired SpinChip Diagnostics ASA, securing a point-of-care immunoassay platform capable of delivering diagnostic results within ten minutes. This integration significantly bolsters the company’s rapid diagnostics portfolio and point-of-care market position. |
| Anbio Biotechnology | Jan-25 | Anbio Biotechnology launched the ADL-1000, a Dry Chemiluminescence Immunoassay solution featuring freeze-dried reagents and whole-blood testing. The system is designed to streamline laboratory workflows and reduce costs, expanding the application of chemiluminescence diagnostics across infectious, cardiovascular, and neurological disease testing. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Immunoassay Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Testing Purpose | Screening & Preventive Testing, Diagnostic Testing, Monitoring & Follow-Up, Research & Drug Development |
| Automation Level | Manual, Semi-Automated, Fully Automated, High-Throughput Automated |
| Purchase Model | Capital Equipment Purchase, Reagent Rental Agreements, Reagent Rental & Placement Contracts, Consumables-Based Procurement |
Immunoassay Market — Custom
| Custom Chapter | Custom Details |
|---|---|
| Laboratory Automation Adoption Outlook |
|
| Diagnostic Testing Workflow and Laboratory Purchasing Analysis |
|
| Decentralized Testing Adoption Landscape |
|
Need a different cut of the data?
Request Custom ResearchWhat is the current size of the immunoassay market?
How much is the immunoassay industry expected to grow by 2036?
How is precision medicine influencing demand in the immunoassay market?
Why are point-of-care immunodiagnostics gaining commercial traction in the immunoassay market?
Why do Reagents & Kits account for the largest share of the immunoassay market?
Which specimen type is growing fastest in the immunoassay market?
Why does North America dominate the immunoassay market?
What is accelerating immunoassay market growth in Asia Pacific?
Who are the leading players in the immunoassay landscape?
Our Clients
"The reports offered a comprehensive view of the Food and Beverage landscape, covering market trends, consumer behavior, and competitive dynamics."
"Our experience in acquiring market research reports has been outstanding — the depth of analysis and actionable insights have proven invaluable."
"Fundamental Business Insights demonstrated a keen understanding of our business needs, delivering reports tailored to our specific objectives."
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Why It Matters | Reference |
|---|---|---|
| World Health Organization (WHO) | Global health statistics, disease burden, healthcare policies | www.who.int |
| U.S. Food & Drug Administration (FDA) | Medical devices, pharmaceuticals, diagnostics, approvals | www.fda.gov |
| European Medicines Agency (EMA) | Pharmaceutical approvals and regulatory guidance in Europe | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | Disease surveillance, public health, epidemiology | www.cdc.gov |
| National Institutes of Health (NIH) | Biomedical research, clinical studies, funding | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | Biomedical databases, PubMed, genomics | www.ncbi.nlm.nih.gov |
| PubMed | Peer-reviewed biomedical literature | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | Global clinical trial registry | clinicaltrials.gov |
| International Organization for Standardization (ISO) | Medical device quality and healthcare standards | www.iso.org |
| ASTM International | Medical device testing and material standards | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | Medical devices and diagnostics industry | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | Medical device innovation and regulatory science | mdic.org |
| Biotechnology Innovation Organization (BIO) | Biotechnology industry developments | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | Global pharmaceutical industry | www.ifpma.org |
| U.S. Pharmacopeia (USP) | Drug quality standards and reference materials | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | European pharmaceutical quality standards | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | Veterinary healthcare and animal diseases | www.woah.org |
| American Hospital Association (AHA) | Hospital operations and healthcare delivery | www.aha.org |
| OECD Health | International healthcare expenditure and system statistics | www.oecd.org/health |
| World Bank Data | Healthcare expenditure and demographic indicators | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization